Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Bioorganic & Medicinal Chemistry
|
September 10, 2011
Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors
Michel C Maillard, Frederick A Brookfield, Stephen M Courtney, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 4, 2025
Orthosteric inhibition of MutSβ ATPase function: First disclosure of MSH3-bound small molecule inhibitors
Gareth N Brace, Karsten Tillack, Peter D Johnson, et al.
Science Translational Medicine
|
February 2, 2022
Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease
Daniele Bertoglio, Jonathan Bard, Manuela Hessmann, et al.
Journal of Medicinal Chemistry
|
April 5, 2011
Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy
Daniel R Chancellor, Kay E Davies, Olivier De Moor, et al.
Scientific Reports
|
September 10, 2021
Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates
Frank Herrmann, Manuela Hessmann, Sabine Schaertl, et al.
Journal of Medicinal Chemistry
|
January 10, 2012
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease
Michael E Prime, Ole A Andersen, John J Barker, et al.
Journal of Medicinal Chemistry
|
January 16, 2015
Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease
Leticia M Toledo-Sherman, Michael E Prime, Ladislav Mrzljak, et al.
Journal of Medicinal Chemistry
|
August 5, 2021
[<sup>11</sup>C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins
Longbin Liu, Peter D Johnson, Michael E Prime, et al.
Journal of Medicinal Chemistry
|
December 22, 2022
Design and Evaluation of [<sup>18</sup>F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin Aggregates
Longbin Liu, Peter D Johnson, Michael E Prime, et al.
Journal of Medicinal Chemistry
|
September 26, 2025
Correction to "Isoindolinone-Based PET Tracers for Imaging Mutant Huntingtin Aggregates"
Longbin Liu, Peter D Johnson, Matthew R Mills, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Bioorganic & Medicinal Chemistry
|
September 10, 2011
Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors
Michel C Maillard, Frederick A Brookfield, Stephen M Courtney, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 4, 2025
Orthosteric inhibition of MutSβ ATPase function: First disclosure of MSH3-bound small molecule inhibitors
Gareth N Brace, Karsten Tillack, Peter D Johnson, et al.
Science Translational Medicine
|
February 2, 2022
Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease
Daniele Bertoglio, Jonathan Bard, Manuela Hessmann, et al.
Journal of Medicinal Chemistry
|
April 5, 2011
Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy
Daniel R Chancellor, Kay E Davies, Olivier De Moor, et al.
Scientific Reports
|
September 10, 2021
Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates
Frank Herrmann, Manuela Hessmann, Sabine Schaertl, et al.
Journal of Medicinal Chemistry
|
January 10, 2012
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease
Michael E Prime, Ole A Andersen, John J Barker, et al.
Journal of Medicinal Chemistry
|
January 16, 2015
Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease
Leticia M Toledo-Sherman, Michael E Prime, Ladislav Mrzljak, et al.
Journal of Medicinal Chemistry
|
August 5, 2021
[<sup>11</sup>C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins
Longbin Liu, Peter D Johnson, Michael E Prime, et al.
Journal of Medicinal Chemistry
|
December 22, 2022
Design and Evaluation of [<sup>18</sup>F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin Aggregates
Longbin Liu, Peter D Johnson, Michael E Prime, et al.
Journal of Medicinal Chemistry
|
September 26, 2025
Correction to "Isoindolinone-Based PET Tracers for Imaging Mutant Huntingtin Aggregates"
Longbin Liu, Peter D Johnson, Matthew R Mills, et al.
Page
of 4